DNTH
NASDAQDianthus Therapeutics Inc.
News · 26 weeks71+1500%
2026-03-012026-08-23
Mix2390d
- Insider9(39%)
- Other7(30%)
- SEC Filings6(26%)
- Offering1(4%)
Latest news
25 items- INSIDERDirector Read Simon sold $326,554 worth of shares (2,778 units at $117.55) as part of a pre-agreed trading plan and exercised 2,778 shares at a strike of $18.36 (SEC Form 4)4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- INSIDERSVP, General Counsel and Sec. Veness Adam M exercised 15,000 shares at a strike of $18.17 (SEC Form 4)4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Dianthus Therapeutics Inc.SCHEDULE 13G - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
- INSIDERDirector Mcgeorge Anne exercised 7,750 shares at a strike of $12.52 and sold $844,822 worth of shares (7,750 units at $109.01) as part of a pre-agreed trading plan (SEC Form 4)4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- INSIDERDirector Read Simon exercised 2,777 shares at a strike of $18.36 and sold $304,232 worth of shares (2,777 units at $109.55) as part of a pre-agreed trading plan (SEC Form 4)4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- INSIDERSVP, General Counsel and Sec. Veness Adam M sold $2,208,833 worth of shares (20,000 units at $110.44) as part of a pre-agreed trading plan and exercised 20,000 shares at a strike of $17.88 (SEC Form 4)4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- SECSEC Form 144 filed by Dianthus Therapeutics Inc.144 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
- PRAgomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of DirectorsAntwerp, Belgium, August 10, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Board of Directors. The appointments will be submitted for shareholder approval at the Company's Special General Meeting to be held on September 11, 2026. "We are delighted to nominate Marino and Naimish to join Agomab’s Board of Directors," said David Epstein, Chairman of the Board of Agomab. "Marino brings extensive experience building, financing and leading inno
- INSIDERCEO AND PRESIDENT Garcia Marino exercised 166,000 shares at a strike of $8.44 and sold $17,945,451 worth of shares (166,000 units at $108.11) as part of a pre-agreed trading plan (SEC Form 4)4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- SECSEC Form 144 filed by Dianthus Therapeutics Inc.144 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
- SECSEC Form 144 filed by Dianthus Therapeutics Inc.144 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
- SECSEC Form 10-Q filed by Dianthus Therapeutics Inc.10-Q - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
- SECDianthus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
- PRDianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial ResultsAdvancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN) Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W initiated in June ‘26, with top-line results anticipated in 2H’28 75% response rate observed in Interim Responder Analysis from first 40 participants completing Part A of Phase 3 CAPTIVATE trial of claseprubart in CIDP, with Part B top-line guidance expected by YE’26 Phase 2 MoMeNtum trial of claseprubart
- PRDianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune DiseasesDNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active C1s (aC1s) and BAFF/APRIL, two validated pathways with complementary disease modifying mechanisms DNTH312 demonstrated comparable in vitro potency and aC1s inhibition to claseprubart, with a comparable non-human primate (NHP) half-life DNTH312 showed similar depth of Ig reductions vs. povetacicept following a single dose in NHPs By building on claseprubart’s best-in-class profile, DNTH312 strengthens Dianthus’ leadership in neuromuscular disease, while expanding into additional autoimmune diseases where both B cell modulation and Classical Pathway inhibition could provide additional benefi
- PRDianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)NEW YORK and WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on August 3, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants consist of non-qualified stock options to purchase an aggregate of 87,000 shares of the Compa
- INSIDEREVP, CFO & CBO Savitz Ryan exercised 31,249 shares at a strike of $21.77 and sold $3,157,151 worth of shares (31,249 units at $101.03) as part of a pre-agreed trading plan (SEC Form 4)4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- PRDianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on July 1, 2026, to five newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants consist of non-qualified stock options to purchase an aggregate of 58,000 shares of the Compan
- PRDianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia GravisEMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, across generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy (MMN) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with best-in-disease, pipeline-in-a-product potential NEW YORK and WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation t
- INSIDERSVP, General Counsel and Sec. Veness Adam M exercised 30,000 shares at a strike of $17.88 and sold $2,423,958 worth of shares (30,000 units at $80.80) as part of a pre-agreed trading plan (SEC Form 4)4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- SECDianthus Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
- INSIDEREVP, Head of R&D Randhawa Simrat exercised 26,530 shares at a strike of $18.85 and sold $2,404,077 worth of shares (26,530 units at $90.62) as part of a pre-agreed trading plan (SEC Form 4)4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- PRDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on June 1, 2026, to three newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants consist of non-qualified stock options to purchase an aggregate of 60,000 shares of the Compa
- PRDianthus Therapeutics to Participate in Two Investor ConferencesNEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in two investor conferences in June 2026. Ryan Savitz, EVP, CFO and CBO of Dianthus Therapeutics, will participate in a fireside chat on Wednesday, June 3, 2026, at 12:45 p.m. ET and will host one-on-one investor meetings at the 2026 Jefferies Global Healthcare Conference. Marino Garcia, CEO of Dianthus Therapeutics, will participate in a fireside chat on Tuesday, June 9, 2026, at 2:40 p.m. ET and
- INSIDERSEC Form 4 filed by Director Lawton Alison Frances4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
DNTH FAQ
6 questionsWhere does DNTH stock trade?
Dianthus Therapeutics Inc. (DNTH) is listed on NASDAQ.What sector and industry is DNTH in?
Dianthus Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Dianthus Therapeutics Inc. go public?
Dianthus Therapeutics Inc. (DNTH) completed its IPO in 2018.What are analysts saying about DNTH?
Dianthus Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-04-09. Recent price targets cluster around $4800.00.What companies are similar to DNTH?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare DNTH side-by-side with any of them on Quantisnow.How can I track DNTH on Quantisnow?
Quantisnow aggregates Dianthus Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DNTH to receive live email and push alerts on every new disclosure.